Development of candidates for new type 2 and type 3 oral poliovirus recombinant vaccines
A number of recombinants between the virulent Mahoney and attenuated Sabin 1 strains of type 1 polioviruses were constructed. Results of biological tests including the monkey neurovirulence test on there recombinant viruses indicated that major determinants of the genome. The viral capsid proteins that contribute to viral antigenicity and immunogenicity, had a little correlation with the neurovirulence or attenuation phenotype of the virus. These results suggested that more safer vaccine strains of the Sabin type 2 and type 3 viruses can be con structed by replacing the sequence of viral capsid proteins of the Sabin 1 poliovirus by the corresponding genome sequences of the Sabin type 2 and type 3. Accordingly, we constructed recombinant viruses between the Sabin type 1 and type 2 or type 3, designated PV1/2(SS)BB and PVl/3(SS)BN, respectively, as candidates for type 2 and type 3 oral poliovirus vaccines. These recombinant viruses had antigenicity and immunogenicity of type 2 and type 3 polioviruses, respectively. The monkey neurovirulence tests and in vitro phenotypic marker tests of these recombinant virsuses indicate that PV1/2(SS)BB and PV1/3(SS)BN are possible candidates for new strain of type 2 and type 3 oral poliovirus vaccine.
KeywordsVaccine Strain Recombinant Virus Oral Poliovirus Vaccine Viral Capsid Protein Live Vaccine Strain
Unable to display preview. Download preview PDF.
- 9.World Health Organization (1983) Requirements for poliomyelitis vaccine (oral). WHO Expert Committee on Biological Standardization. Annex 4. Tech Rep Ser 687: 107–165Google Scholar